Janssen's EGFR/c-MET Bispecific Antibody Amivantamab Plus Lazertinib Demonstrates Superior PFS vs Osimertinib in Phase III MARIPOSA Study for First-Line EGFR-Mutant NSCLC
Johnson & Johnson
Healthcare Product Manufacturers, Health Service Providers
On September 28, Johnson & Johnson announced that the Phase III MARIPOSA study evaluating Rybrevant (amivantamab), an EGFR/c-MET bispecific antibody, in combination with the third-generation EGFR inhibitor Lazertinib versus osimertinib for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), achieved positive topline data.
The results showed that the MARIPOSA study achieved its primary endpoint, compared withOsimertinib Treatment GroupIn comparison,Rybrevant+Lazertinib treatment group showed statistically significant and clinically meaningful improvement in progression-free survival (PFS). In terms of safety,Rybrevant+LazertinibThe safety of combination therapy is consistent with previously reported data.
In addition, the interim overall survival (OS) analysis showed that, compared withOsimertinib Treatment GroupPhaseCompared to，Rybrevant+LazertinibThe treatment group showed a trend of benefit in OS.
It is worth mentioning that Johnson & Johnson also announced this monthRybrevant CombinationLazertinib and ChemotherapyThe Phase III MARIPOSA-2 Study for Treating Osimertinib Resistance Met the Primary Endpoint of PFS.MARIPOSA-2 has also become the first Phase III study to demonstrate a clinically meaningful improvement in PFS for osimertinib in later-line treatment (Johnson & Johnson's EGFR/c-MET Bispecific Antibody Combination Therapy Successful in Phase III Study for Second-Line Treatment of NSCLC）。
Copyright © 2023 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
PharmaCube Reader Survey Questionnaire
Thank you for your companionship and we look forward to your feedback.
Scan the QR code to provide valuable suggestions
